Structural proteins

Seratopical Revolution Skincare Line by The Sera Labs Inc., a CURE Pharmaceutical Company, will be Available for Purchase this Fall at CVS, one of the Leading National Drug Store Chains

Retrieved on: 
Wednesday, August 4, 2021

CVS is one of the leading national drug store chains in America.

Key Points: 
  • CVS is one of the leading national drug store chains in America.
  • Seratopical Revolution marries nature and science into one clean and nourishing line of beauty products.
  • Our formulators have developed a proprietary high-tech delivery system which allows the ingredients to go deep into the skin.
  • Our loyal customers will benefit from scientifically backed ingredients that are designed to enhance hydration and rejuvenate collagen.

Collagen Matrix Names Jessica Swanson Vice President of Marketing

Retrieved on: 
Tuesday, August 3, 2021

OAKLAND, N.J., Aug. 3, 2021 /PRNewswire/ --Collagen Matrix, Inc., a leader in regenerative medicine, global manufacturer of collagen- and mineral-based medical devices, and Linden Capital Partners portfolio company, announced today the appointment of Jessica Swanson as Vice President of Marketing.

Key Points: 
  • OAKLAND, N.J., Aug. 3, 2021 /PRNewswire/ --Collagen Matrix, Inc., a leader in regenerative medicine, global manufacturer of collagen- and mineral-based medical devices, and Linden Capital Partners portfolio company, announced today the appointment of Jessica Swanson as Vice President of Marketing.
  • Jessica Swanson is a senior marketing executive dedicated to improving lives globally through the development, commercialization, and impact of innovative healthcare devices and products.
  • Most recently, Jessica served as Vice President of Global Marketing for the Breast and Skeletal Health Division at Hologic, Inc., leading a dynamic team focused on product management, integrated brand marketing, medical education, and sales training.
  • Collagen Matrix, Inc. is a developer and manufacturer of collagen-based medical products used for tissue and bone repair and regeneration.

Global Collagen & Gelatin (Bovine, Porcine, Marine) Markets, 2021-2026: Focus on Wound Care, Orthopedic, Cardiovascular Disease, Dental, Surgical, Dural - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 27, 2021

The "Global Collagen & Gelatin Market by Source (Bovine, Porcine, Marine), Application (Wound Care, Orthopedic, Cardiovascular Disease, Dental, Surgical, Dural), End-user (Hospitals, Surgical Centers), and Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Collagen & Gelatin Market by Source (Bovine, Porcine, Marine), Application (Wound Care, Orthopedic, Cardiovascular Disease, Dental, Surgical, Dural), End-user (Hospitals, Surgical Centers), and Region - Forecast to 2026" report has been added to ResearchAndMarkets.com's offering.
  • The global collagen and gelatin market is projected to reach USD 1,083 million by 2026 from USD 772 million in 2021, at a CAGR of 7% during the forecast period.
  • Based on application, the global collagen market is segmented into orthopedic, wound care, dental, surgical, cardiovascular, and other applications.
  • The collagen and gelatin market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period.

Bloom Beauty Essence® – Radiant Skin Combats Everything that Attacks Your Skin

Retrieved on: 
Thursday, July 22, 2021

A German pharmaceutical company, R-Pharm, has created Bloom Beauty Essence which provides day and night protection through a superfood supplement and collagen drink to make your skin radiant.

Key Points: 
  • A German pharmaceutical company, R-Pharm, has created Bloom Beauty Essence which provides day and night protection through a superfood supplement and collagen drink to make your skin radiant.
  • Steiner-Kienzler said R-Pharm developed Bloom Beauty Essence products to reduce wrinkles, increase skin resistance and tighten your bodys skin.
  • Bloom Beauty Essence Night Spa naturally rejuvenates your skin by using superfoods, such as pomegranate and gluten-free wheat extracts, Steiner-Kienzler said.
  • Bloom Beauty Essence Skin Care Drink With Collagen, which provides an extra boost during the day,comes in regular and low-calorie versions.

ProMIS Neurosciences to Present at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Thursday, July 22, 2021

TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.

Key Points: 
  • TORONTO and CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, will give two presentations at the annual Alzheimers Association International Conference (AAIC) to be held July 26-30, 2021 in Denver, USA and online.
  • ProMIS Chief Scientific Officer, Dr. Neil Cashman will give an oral presentation entitled: Selective targeting of intracellular misfolded, pathogenic TDP-43 with rationally designed intrabodies.
  • Dr. Johanne Kaplan, ProMIS Chief Development Officer, will present the poster entitled: Conformational epitopes exposed on misfolded toxic forms of amyloid-beta, tau and alpha-synuclein directly contribute to their seeding activity.
  • Both presentations will be available on the ProMIS website ( www.promisneurosciences.com ) after the AAIC closes on July 30.

The Ingredient Transparency Center's Collagen Stewardship Alliance Adds BioCell Technology to its Supporter List

Retrieved on: 
Thursday, July 15, 2021

SPRING, Texas, July 15, 2021 /PRNewswire/ --Today, the Ingredient Transparency Center's Collagen Stewardship Alliance (CSA) announced that BioCell Technology, LLC has signed on as a Sponsor Level supporter.

Key Points: 
  • SPRING, Texas, July 15, 2021 /PRNewswire/ --Today, the Ingredient Transparency Center's Collagen Stewardship Alliance (CSA) announced that BioCell Technology, LLC has signed on as a Sponsor Level supporter.
  • BioCell Collagen is a clinically studied dietary supplement ingredient comprised of a complex matrix of primarily collagen type II peptides, chondroitin sulfate and hyaluronic acid.
  • "BioCell's values surrounding attribution of science and commitment to the collagen category align closely with CSA's and we're pleased to add them to our supporter roster," said Len Monheit, CEO, Trust Transparency Center and management lead for the Collagen Stewardship Alliance.
  • BioCell Collagen is a clinically studied dietary ingredient composed of naturally occurring hydrolyzed collagen type II peptides, chondroitin sulfate, hyaluronic acid.

NEWA - The world's first RF based energy device cleared by the FDA, over the counter home use wrinkle reduction

Retrieved on: 
Wednesday, June 23, 2021

The NEWA, is the world's first device of its kind to be cleared by the FDA for over the counter home use for mild to moderate wrinkle reduction.

Key Points: 
  • The NEWA, is the world's first device of its kind to be cleared by the FDA for over the counter home use for mild to moderate wrinkle reduction.
  • Based on EndyMed's patented 3DEEP radiofrequency (RF) technology , the NEWA home use device is clinically proven to reduce wrinkles, lift and tighten the skin, contour cheekbones and jawline, and give an amazing glow.
  • EndyMed's unique 3DEEP RF technology incorporated into the NEWA delivers focused, controlled energy deep into the skin, promoting natural new collagen regeneration.
  • The NEWA is the world's first home device that uses the same medical grade RF technology used in high end professional clinics.

Mallinckrodt Announces U.S. FDA Approval of StrataGraft® (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat)

Retrieved on: 
Wednesday, June 16, 2021

"The approval of StrataGraft represents an important advancement in the treatment of patients with deep partial-thickness burns.

Key Points: 
  • "The approval of StrataGraft represents an important advancement in the treatment of patients with deep partial-thickness burns.
  • StrataGraft is a viable, bioengineered, allogeneic, cellularized scaffold product derived from keratinocytes grown on gelled collagen containing dermal fibroblasts.
  • At the time of approval, the FDA awarded Stratatech Corporation, a Mallinckrodt company, a Priority Review Voucher (PRV).
  • Do not use in patients with known allergies to murine collagen or products containing ingredients of bovine or porcine origin.

Insights on the Collagen Supplement Global Market to 2027 - Opportunity Analysis and Industry Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021

The "Collagen Supplement Market by Source, Form and Concentration: Global Opportunity Analysis and Industry Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Collagen Supplement Market by Source, Form and Concentration: Global Opportunity Analysis and Industry Forecast, 2021-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global collagen supplement market was valued at $1,827.6 million in 2019, and is projected to reach $3,017.6 million by 2027, registering a CAGR of 6.9%.
  • However, high cost of collagen supplements and growing adoption of veganism act as the major restraint for the collagen supplement market growth.
  • The market player positioning segment facilitates benchmarking and provides a clear understanding of the present position of the market players in the collagen supplement industry.

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

Retrieved on: 
Friday, June 4, 2021

The presentation will include interim data from the ongoing dose-escalation portion of Intellias Phase 1 trial evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN).

Key Points: 
  • The presentation will include interim data from the ongoing dose-escalation portion of Intellias Phase 1 trial evaluating NTLA-2001 in people living with hereditary ATTR amyloidosis with polyneuropathy (hATTR-PN).
  • Following safety assessment and dose optimization, Intellia intends to further evaluate NTLA-2001 in a broader population of people with ATTR amyloidosis, including those with cardiomyopathy.
  • Intellia will host a live webcast on Monday, June 28, 2021 at 8:00 a.m. E.T.
  • Intellias global Phase 1 trial is an open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN).